secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tourmaline Bio, Inc. (—)
CIK:        0001827506
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0000950170-23-012932
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talaris eliminates ~95% of remaining workforce; CEO and three other executives depart
--------------------------------------------------------------------------------

- April 2023 reduction of ~80 employees (95% of remaining staff); total severance costs estimated at $8.7M through Q2 2023.
- CEO Scott Requadt, CMO Nancy Krieger, CTO Michael Zdanowski, and CHRO Andrew Farnsworth all leaving company.
- CFO Mary Kay Fenton enters retention agreement; eligible for cash bonus upon strategic transaction or liquidation.
- Prior February reduction cut ~1/3 of workforce; company continues evaluating strategic alternatives.
- Reduction substantially complete by May 26, 2023; WARN Act severance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/tals-20230414.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-012932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer